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Abstract
Background: Oncotype DX testing has reduced the use of adjuvant chemotherapy in
node-negative early breast cancer but less is known about its impact in node positive
patients.
Aim: This study aimed to investigate the impact of Oncotype DX gene assay testing
on the decision to offer adjuvant chemotherapy in oestrogen positive, human epider-
mal growth factor receptor 2 negative, 1–3 lymph node positive patients.
Methods: Retrospective review of all node positive patients who underwent
Oncotype DX testing at a single centre. Clinicopathological data, as well as estimated
survival benefit data (from the PREDICT tool), was evaluated by a multidisciplinary
group of surgeons and oncologists. Treatment decisions based on clinicopathological
data were compared to recurrence scores (RS). A cut off RS > 30 was used to offer
adjuvant chemotherapy.
Results: The 69 patients were identified, of which 9 (13%) had an RS > 30 and
assigned a high-genomic risk of recurrence. The 32 patients (46.4%) were offered
adjuvant chemotherapy. Overall based on the use of the RS, the decision to offer
adjuvant chemotherapy changed in 36% of patients, and ultimately 24 patients
(34.7%) would have been spared chemotherapy.
Conclusion: Using clinicopathological data alone to make decisions regarding adju-
vant chemotherapy in node positive breast cancer leads to overtreatment. Additional
information on tumour biology as assessed by the Oncotype DX RS helps to select
those patients who will benefit from adjuvant chemotherapy and spare patients from
unnecessary chemotherapy.
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1 | INTRODUCTION
Recent advances in our understanding of early breast cancer have
shown it to be a heterogeneous disease with tumour biology
becoming a more important factor in determining clinical course,
response to treatment and long-term survival.1–3
Traditionally the decision for adjuvant chemotherapy in early
breast cancer has largely relied on prognostic information based on
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clinicopathological features of the patient and tumour. More recently,
gene expression profiling which captures tumour biology has been
increasingly used to aid clinical decision-making.
The Oncotype DX test (Genomic Health, Redwood City, CA, USA)
is a reverse transcriptase polymerase chain reaction based assay
which measures the expression of a panel of 21 genes (16 cancer-
related, five reference) and generates a recurrence score (RS)–a value
from 0 to 100.4 This score reveals underlying tumour biology and also
represents an individualised estimate of the risk of disease recurrence
and prognosis.
Previous work with ER+, HER2-, node-negative patients has
shown that the RS accurately predicts the benefit of adjuvant chemo-
therapy helping identify patients who would not benefit from the
addition of chemotherapy to adjuvant endocrine therapy. In the land-
mark TAILORx trial, it was shown that ER+, HER2-, node-negative
women with RS 0–15, and women above age 50 with RS 0–25 did
not benefit from adjuvant chemotherapy with no difference in survival
compared to endocrine therapy alone.5 Multiple studies have shown
the use of Oncotype DX testing in the node-negative setting has
changed treatment decisions in up to 30% of patients.6–8
More recently, attention has turned to the utility of the RS in
node positive patients, to try to identify patients who would benefit
from adjuvant chemotherapy.9
Retrospective data from the SWOG-8814 trial found that only ER
+, HER2-, node positive patients identified as high risk, which was
defined as a RS >30, benefitted from the addition of adjuvant chemo-
therapy compared to tamoxifen alone.10 There was no benefit from
the addition of adjuvant chemotherapy in low risk patients (RS < 18)
or for the intermediate (RS 18–30) group, although this trial was
underpowered to detect a subtle difference.
The prospective WSG/planB trial showed that node positive
patients with a RS < 11 had excellent (94.3%) 5-year disease free sur-
vival without chemotherapy.11 Patients with intermediate-risk
(defined as RS 12–25) underwent chemotherapy and showed a similar
5-year disease free survival of 94.3% suggesting that there may be
some benefit of chemotherapy in this group. The ongoing RxPONDER
trial is evaluating the role of adjuvant chemotherapy in node positive
patients with a RS ≤25.9 Patients will be randomised to hormonal
therapy with or without adjuvant chemotherapy. The estimated com-
pletion date for the trial is 2022.12
From these studies, it is clear that gene expression profiling has a
role in guiding treatment selection of node positive patients to iden-
tify those patients who would not benefit from chemotherapy.9,13
More evidence to support this is still needed.
Decisions about breast cancer treatment are made by a multi-
disciplinary team (MDT) including breast surgeons and oncologists. In
addition to clinicopathological data, standard UK practice is to use, a
prognostication tool such as PREDICT to aid decision making.14 This
model uses various clinicopathological features to derive estimates for
10-year survival and quantify the benefits of the addition of adjuvant
chemotherapy.15
Our breast cancer MDT is one of the early adopters of Oncotype
DX testing in a selected group of node positive patients since 2014.
Patients were selected for Oncotype DX testing if the MDT felt there
was a benefit in further information to aid decision making of adjuvant
chemotherapy.
The current study aims to examine the real-life impact of
Oncotype DX testing on the decision to offer adjuvant chemotherapy
to ER+ HER2- node positive patients compared to decisions made by
a simulated MDT based solely on clinicopathological data.
2 | METHODS
A retrospective cohort study was conducted at Norfolk and Norwich
University Hospitals NHS Trust, a tertiary teaching hospital treating
approximately 700 new breast cancer patients per year. All patients
with ER+, HER2-, 1–3 lymph node positive breast cancer who under-
went Oncotype DX testing between July 2014 and April 2020 were
identified from a prospectively maintained database. All patients
underwent appropriate surgery to remove the primary breast tumour
and either sentinel lymph node biopsy or axillary clearance. Patients
were selected to undergo Oncotype testing by a contemporaneous
MDT if it was felt that additional information from the test would
guide decisions to offer or omit adjuvant chemotherapy in patients
with intermediate-risk. Patients with micrometastases or isolated
tumour cells were excluded. Patients with four or more lymph nodes
and/or distant metastases were excluded.
Clinical data were collected for each patient including age, multi-
focality of disease, tumour histology, tumour grade, size of tumour,
presence of lymphovascular invasion, ER positivity/Allred Quick score,
number of positive nodes and details of treatment to date. Further-
more, estimates of 10-year survival and the added benefit of adjuvant
chemotherapy were recorded for all patients using the online PRE-
DICT tool (breast.predict.nhs.uk).
RS calculated from the Oncotype DX test (Genomic Health, Red-
wood City, CA, USA) performed on each tumour were also collected.
A simulated MDT panel composed of three members (two oncol-
ogists, one surgeon) reviewed the available clinicopathological for
each patient and estimated survival data, before making a recommen-
dation of whether to offer adjuvant chemotherapy or not. PREDICT
scores were available to the simulated MDT members. The members
of the MDT panel were blinded to the RS for each patient.
The simulated MDT decision to offer adjuvant chemotherapy was
compared to the RS recommendation for chemotherapy. A RS of
greater than 30 was used to select high-risk patients who would ben-
efit from chemotherapy based on previous studies.10
The two decisions were compared for each patient aiming to
examine the impact of the Oncotype DX test in real life.
2.1 | Statistical analysis
Statistical analysis was performed using Microsoft Excel (Microsoft
Corporation, Redmond, VA). A p value of <.05 was taken as statistical
significance. The Mann–Whitney U test was used for continuous
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variables, whilst Fisher's exact test and Chi-squared test was used for
categorical variables.
2.2 | Cost analysis
A cost analysis to assess the financial impact of Oncotype testing was
performed using previously published sources. The current list price
to the NHS for the Oncotype DX test is £2580.16 The full cost of a
course of chemotherapy, including drug costs, delivery costs and tox-
icity, is estimated to be between £3866.17 and £4863.70 depending
on regimen.16,17 The cost of performing the Oncotype DX test on all
patients in the cohort was compared to the potential savings of omit-
ting chemotherapy in patients with a low RS. Further subgroup cost
analysis excluding patients with favourable PREDICT scores
(<2% predicted survival benefit) was also performed.
3 | RESULTS
A total of 69 patients with ER+, HER2-, and 1–3 lymph node positive
breast cancer were referred for Oncotype DX testing during the
period between July 2014 and April 2020. The median age was
61 years (range, 33–76 years). Fifty-five patients (79.7%) had one
positive lymph node, 12 patients (17.3%) had two positive lymph
nodes and two patients had three positive lymph nodes. The median
Oncotype DX RS was 16 with a range of 0–63.
In 32 patients (46.4%), the simulated MDT recommended adju-
vant chemotherapy. Figure 1 shows the number of patients offered
adjuvant chemotherapy by the MDT based on stratification by geno-
mic risk based on traditional RS cut-offs. Using a threshold RS > 30,
nine patients (13%) were considered as high genomic risk patients
who would benefit from adjuvant chemotherapy, whereas
patients with an RS < 30 were considered low risk based on current
evidence.
Table 1 summarises clinicopathological data for included patients
and their PREDICT scores.
Patients in the high genomic risk group (RS > 30) were more likely
to present with symptoms (p = .0353) and with a higher tumour grade
(p = .0003). No patients in the high-genomic risk group had Grade 1
tumours. Estimated additional 10-year overall survival benefit as cal-
culated using the PREDICT tool was moderately correlated with RS
(r2 = 0.44, p = .02). All patients with a PREDICT score indicating >5%
survival benefit with chemotherapy were recommended to undergo
adjuvant chemotherapy by the simulated MDT (Supplementary
Figure S1).
Concordance between the MDT decision and RS recommenda-
tion regarding the decision to offer adjuvant chemotherapy to
patients or not was reached in 44 patients (63.7%). Conversely, dis-
cordance between the MDT decision and RS was observed in
25 patients (36.3%). In the vast majority of these cases (24/25
patients) the simulated MDT recommended offering adjuvant chemo-
therapy to patients with a low RS, indicating that these patients are
unlikely to benefit from chemotherapy. Overall, based on the use of
the RS the decision to offer adjuvant chemotherapy changed in 36%
of patients, and ultimately 24 patients (34.7%) would have been
spared chemotherapy.
The simulated MDT outcomes were compared to the real life
contemporaneous outcomes where the MDT panel had knowledge of
Oncotype scores. All patients in the high RS group who were rec-
ommended for adjuvant chemotherapy actually received chemother-
apy. In the low RS group, 5 out of 24 patients recommended for
adjuvant chemotherapy by the simulated MDT underwent chemo-
therapy in real life.
Using the current NHS list price, the Oncotype DX test costs
£2580, which reflects a total cost of £178 020 to test our cohort.
From previous studies, the cost of a course of adjuvant chemotherapy
in breast cancer is estimated to be between £3866.17 and £4863.70
depending on regimen.16,17 In our study, 32 patients were rec-






















F IGURE 1 Graph showing the
distribution of patients by RS into
low, intermediate and high risk
groups. Breakdown of each group by
the number of patients recommended
to undergo adjuvant chemotherapy
based on the multidisciplinary team
(MDT) decision
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RS > 30. Therefore, the potential saving in chemotherapy costs is
£88921.91 to £111865.10.
Excluding patients with favourable PREDICT scores from
Oncotype testing may improve cost effectiveness. Omitting the
25 patients that had a predicted survival benefit of ≤2% after
the addition of adjuvant chemotherapy (and who the simulated MDT
did not recommend chemotherapy to) would yield a cost of £113 520
to Oncotype test the remainder of patients, and is more comparable
to the chemotherapy savings. However, one patient in the favourable
PREDICT score cohort had a RS > 30 and would have potentially mis-
sed out on chemotherapy.
4 | DISCUSSION
Our study shows that the Oncotype DX test changed the decision to
offer adjuvant chemotherapy in more than one-third of patients with
ER+ HER2- tumours and 1–3 involved nodes. In the vast majority of
cases, the MDT recommended adjuvant chemotherapy to patients
with low RS scores. This is broadly in keeping with other studies
looking at treatment decisions in node-negative breast cancer.6,18,19
Few published studies have examined the role of Oncotype Dx
testing in the node positive setting. Interim results of a UK based trial
show that the decision to administer adjuvant chemotherapy changed
in 74% of patients, sparing them from chemotherapy.20 A US-based
study found that RS was an independent predictor of chemotherapy
recommendation in 1–3 node positive patients.21
Similar to other studies, we found that the majority of node-
positive patients have a low-risk genomic signature as assessed by the
Oncotype Dx test. Despite this, over 50% of patients in the low risk
group with an RS <18 were offered adjuvant chemotherapy by
the MDT.
A significant proportion of patients fell into the intermediate-risk
group with an RS 18–30, and there are ongoing trials to determine
whether there is a subgroup of these patients who may benefit from
adjuvant chemotherapy. The patients in this group represent a real
challenge for breast MDTs. The highly anticipated results from the
RxPONDER trial will help inform the role of adjuvant chemotherapy
in patients with RS <25.
There is also variability in the RS cut-off values used amongst dif-
ferent studies. The initial SWOG-8814 trial used a definition of
RS > 30 to define patients at high risk of recurrence,10 however, data
suggests that decisions about adjuvant chemotherapy are being made
using the inclusion criteria of the RxPONDER trial with a lower
threshold of 25.21 Further studies will be needed to robustly define
high and low-risk groups based on RS.
We found a moderately positive correlation between estimated
additional 10-year overall survival benefit based on PREDICT and
TABLE 1 Table summarising the
clinicopathological data high recurrence








score > 30 p value
N 69 60 9
Median age (range) 61 (33–76) 59 (33–76) 63 (39–74) .0819a
Detected by screening 31 30 1 .0353b
Detected by symptoms 38 30 8
Grade
Grade 1 19 19 0 .0003c
Grade 2 35 33 2
Grade 3 15 8 7
Median tumour size in mm
(range)
19 (8–65) 18 (8–65) 25 (13–28) 0.3735a
Lymphovascular invasion
present






3(1–32) 3 (1–23) 3 (1–32) 0.3077a
Nodes positive (range) 1(1–3) 1 (1–3) 1 (1–2) 0.6031a
PREDICT score benefit
<2% 14 14 0 .0195c
2%–5% 40 36 4
>5% 15 10 5
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RS. To the best of our knowledge, this is the first to examine this rela-
tionship in node-positive patients. Previous studies in node-negative
patients have shown a correlation between RS and low-risk patients,
but discordance in high-risk patients.22,23
This study is one of the very few showing real-life data on the
effect of Oncotype test on adjuvant chemotherapy decisions in 1–3
node positive patients. The management of micrometastases or iso-
lated tumour cells in the axilla remains contentious24,25 and therefore
were excluded from our study. In patients with four or more lymph
nodes involved, most MDTs would recommend adjuvant chemother-
apy without the need to resort to genetic assessment tests such as
Oncotype. By excluding these two categories of patients, we avoid
confounding factors into our data.
There are some limitations in this study. Firstly, a relatively small
number of node positive patients were tested and the study was ret-
rospective in nature. There is also selection bias, as the contempora-
neous MDT selected patients for Oncotype DX testing on a case by
case basis where the decision to offer adjuvant chemotherapy was
uncertain and genomic testing was felt to aid decision making.
Additionally, our study did not measure the oncologic or long-
term outcomes in this group of patients as our main focus is on
assessing the impact of Oncotype on the decision to offer adjuvant
chemotherapy.
Our present study does not show clear-cut cost-effectiveness in
node-positive patients, which had been reported by other studies.26
However, we have not included the potential costs of toxicities
incurred by patients who would unnecessarily undergo chemotherapy
(i.e., low RS patients). Additionally, our data does support targeted
testing of node-positive patients; including omitting testing for
patients with favourable PREDICT scores that do not predict much
benefit from the addition of adjuvant chemotherapy. Omitting these
patients and those assessed as low risk by traditional clinicopathologi-
cal features27may improve cost-effectiveness.
Another limitation of our study is that patient preferences were
not taken into account in the cost effectiveness of oncotype testing
and chemotherapy usage.
The strengths of this study are that it reflects the real-life practice
and decision making by using actual patient data with members of the
simulated MDT panel blinded to the RS to minimise bias. Our study
shows that the use of Oncotype DX in selected node positive patients
reduces adjuvant chemotherapy use by objectively identifying those
patients with a high risk of recurrence.
The use of gene assays in the management of node-negative breast
cancer has been enshrined in multiple national and international guide-
lines. NICE guidelines have recommended Oncotype DX testing as an
option for node-negative patients with intermediate-risk of recurrence
to help aid decisions about adjuvant chemotherapy.28 As more robust
prospective data supporting Oncotype testing in node positive patient
emerges it will help inform the future revision of these guidelines.13
Advances in modern oncology with the increasing use of targeted
therapies and novel prognostic markers will ultimately result in more
personalised approaches to the treatment of breast cancer patients.
Gene-based assays such as Oncotype DX provide additional valuable
information on individual tumour biology and prognosis. Given the
short and long term toxicity associated with adjuvant chemotherapy,
it is imperative to identify patients who have a high risk of recurrence
and therefore most likely to benefit, as well as identify low-risk
patients in whom chemotherapy can be safely omitted. Our study
shows that decision-making based solely on clinicopathological data
may lead to overtreatment of node positive patients. However, pro-
spective randomised trial data is still lacking. The results of ongoing
trials, such as RxPonder, are eagerly anticipated to fully inform the
role of Oncotype DX testing in node positive patients.
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